Indicaciones de la combinación de pravastatina y fenofibrato según el nivel de riesgo cardiovascular. Situaciones clínicas habituales
Indications for the combination of pravastatin and fenofibrate according to the cardiovascular risk level. Common clinical situations
Xavier Pintó
Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna, Hospital Universitari de Bellvitge, L´Hospitalet de Llobregat, Barcelona, España. CIBERobn, FIPEC, IDIBELL, Universitat de Barcelona, Barcelona, España
Leído
1486
Vecesse ha leído el artículo
577
Total PDF
909
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 10 | 9 | 19 |
| 2025 11 | 42 | 38 | 80 |
| 2025 10 | 25 | 9 | 34 |
| 2025 9 | 22 | 10 | 32 |
| 2025 8 | 21 | 11 | 32 |
| 2025 7 | 14 | 10 | 24 |
| 2025 6 | 15 | 4 | 19 |
| 2025 5 | 11 | 4 | 15 |
| 2025 4 | 12 | 3 | 15 |
| 2025 3 | 7 | 3 | 10 |
| 2025 2 | 11 | 3 | 14 |
| 2025 1 | 6 | 0 | 6 |
| 2024 12 | 6 | 3 | 9 |
| 2024 11 | 9 | 4 | 13 |
| 2024 10 | 5 | 2 | 7 |
| 2024 9 | 9 | 7 | 16 |
| 2024 8 | 12 | 3 | 15 |
| 2024 7 | 8 | 4 | 12 |
| 2024 6 | 6 | 5 | 11 |
| 2024 5 | 7 | 6 | 13 |
| 2024 4 | 5 | 4 | 9 |
| 2024 3 | 12 | 7 | 19 |
| 2024 2 | 10 | 3 | 13 |
| 2024 1 | 4 | 2 | 6 |
| 2023 12 | 4 | 6 | 10 |
| 2023 11 | 9 | 3 | 12 |
| 2023 10 | 14 | 19 | 33 |
| 2023 9 | 9 | 1 | 10 |
| 2023 8 | 6 | 1 | 7 |
| 2023 7 | 3 | 3 | 6 |
| 2023 6 | 3 | 5 | 8 |
| 2023 5 | 16 | 2 | 18 |
| 2023 4 | 9 | 3 | 12 |
| 2023 3 | 4 | 2 | 6 |
| 2023 2 | 5 | 2 | 7 |
| 2022 1 | 8 | 4 | 12 |
| 2022 12 | 7 | 8 | 15 |
| 2022 11 | 9 | 5 | 14 |
| 2022 10 | 7 | 7 | 14 |
| 2022 9 | 4 | 15 | 19 |
| 2022 8 | 8 | 8 | 16 |
| 2022 7 | 8 | 7 | 15 |
| 2022 6 | 7 | 9 | 16 |
| 2022 5 | 8 | 11 | 19 |
| 2022 4 | 6 | 20 | 26 |
| 2022 3 | 5 | 4 | 9 |
| 2022 2 | 3 | 4 | 7 |
| 2019 12 | 1 | 0 | 1 |
| 2018 4 | 1 | 1 | 2 |
| 2018 3 | 0 | 1 | 1 |
| 2018 1 | 0 | 4 | 4 |
| 2017 12 | 1 | 2 | 3 |
| 2017 11 | 1 | 2 | 3 |
| 2017 10 | 1 | 1 | 2 |
| 2017 9 | 0 | 5 | 5 |
| 2017 8 | 4 | 2 | 6 |
| 2017 7 | 2 | 3 | 5 |
| 2017 6 | 1 | 4 | 5 |
| 2017 5 | 1 | 0 | 1 |
| 2017 4 | 1 | 2 | 3 |
| 2017 3 | 8 | 10 | 18 |
| 2017 2 | 10 | 3 | 13 |
| 2016 1 | 2 | 0 | 2 |
| 2016 12 | 5 | 3 | 8 |
| 2016 11 | 14 | 2 | 16 |
| 2016 10 | 13 | 4 | 17 |
| 2016 9 | 9 | 3 | 12 |
| 2016 8 | 13 | 3 | 16 |
| 2016 7 | 11 | 3 | 14 |
| 2016 6 | 18 | 25 | 43 |
| 2016 5 | 24 | 11 | 35 |
| 2016 4 | 19 | 17 | 36 |
| 2016 3 | 20 | 9 | 29 |
| 2016 2 | 23 | 22 | 45 |
| 2015 1 | 18 | 25 | 43 |
| 2015 12 | 18 | 15 | 33 |
| 2015 11 | 18 | 12 | 30 |
| 2015 10 | 25 | 7 | 32 |
| 2015 9 | 16 | 9 | 25 |
| 2015 8 | 14 | 6 | 20 |
| 2015 7 | 15 | 6 | 21 |
| 2015 6 | 10 | 6 | 16 |
| 2015 5 | 17 | 5 | 22 |
| 2015 4 | 13 | 7 | 20 |
| 2015 3 | 16 | 9 | 25 |
| 2015 2 | 15 | 8 | 23 |
| 2015 1 | 13 | 3 | 16 |
| 2014 12 | 12 | 4 | 16 |
| 2014 11 | 12 | 1 | 13 |
| 2014 10 | 8 | 2 | 10 |
| 2014 9 | 4 | 2 | 6 |
| 2014 8 | 8 | 0 | 8 |
| 2014 7 | 3 | 5 | 8 |
Mostrar todo